Merck (NYSE: MRK) Posts Bigger Profit in 3Q

Boca Raton, Florida 10/22/2009 06:35 PM GMT (TransWorldNews)

Merck & Co. (NYSE: MRK) on Thursday posted a bigger profit in the third quarter due to slightly higher sales and a huge gain from selling a business, according to Associated Press.

TNT Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.

Sign Up for our Free Stock Newsletter

Merck, the maker of cholesterol drugs, vaccines and asthma and allergy treatment Singulair, said net income was $3.42 billion, more than triple the $1.09 billion it made a year earlier.

That's mostly due to Merck having to sell its half of the Merial animal health business so that regulators would approve its plan to buy New Jersey neighbor Schering-Plough Corp. (NYSE: SGP).

That sale brought in $2.8 billion, or $1.7 billion after taxes. Without it, profit would have been up roughly 58 percent from the 2008 third quarter.

Merck is about to leapfrog from No. 8 to No. 2 in the pharmaceutical industry with its pending $41.1 billion acquisition of Schering-Plough. That will put it right behind Pfizer Inc., which last week bought Wyeth for $68 billion.

For the third quarter, Merck posted a 2 percent increase in revenue, to $6.05 billion.

It had earnings per share of $1.61, or 90 cents excluding the big gain from Merial. That beat analysts' conservative expectations for earnings per share of 82 cents without items and revenue of $6 billion.

Its diabetes drugs, Januvia and Janumet, saw big jumps, bringing in a combined $664 million, and Januvia was recently approved in China. Sales of Merck's top drug, Singulair, increased 5 percent to $1.1 billion. HIV drug Isentress was up 84 percent to $197 million, but sales of osteoporosis blockbuster Fosamax, which now has generic competition, fell 22 percent to $276 million.

Gardasil, a vaccine against a virus that causes cervical cancer and genital warts, had a 22 percent drop in sales to $311 million. Gardasil got off to a strong start when it was launched three years ago, but has seen sales slump this year and took two potential blows to sales in the last week.

Last Friday, GlaxoSmithKline PLC's rival HPV vaccine, Cervarix, got approved by the Food and Drug Administration. Then on Wednesday, the U.S. Advisory Committee on Immunization Practices decided not to recommend routine vaccination of boys to prevent them from getting genital warts or infecting girls with HPV. That's despite the FDA approving Gardasil for boys a week ago.

Meanwhile, concerns about the swine flu epidemic have boosted sales of another Merck vaccine, Pneumovax, which protects against 23 strains of pneumococcal disease that can cause pneumonia. Sales are up about 80 percent from a year ago, to $130 million, as government agencies have been buying the vaccine and health officials push steps to prevent pneumonia, a common flu complication that can be deadly.

Merck and Schering-Plough have been partners for several years on the cholesterol drugs Vytorin and Zetia, but their once-surging sales have been declining steadily since January 2008. In the third quarter, their combined sales fell nearly 7 percent, to $1.03 billion.

Sign up for TNT Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.

About Us

TNT Stocks is a leading stock web site that tracks small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.

Please click here to read the full disclaimer

www.tntstocks.com

Empty Image

Email Article to a friend | View Profile

Visit Blogs |